GlassScriptPhysician profile
Kristin Giannini
NPI 1881662443
$28,484.05
in general payments reported to CMS, 2019-2025
85 companies · $3,862 in 2025
The $3,862 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,369 · 2020: $4,099 · 2021: $3,877 · 2022: $3,774 · 2023: $4,130 · 2024: $4,373 · 2025: $3,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,194.79 |
| Education | $170.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,001.66 | 2019-2025 | |
| Novo Nordisk INC | $3,065.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,548.26 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Pfizer INC. | $1,864.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,369.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,237.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,066.65 | 2019-2025 | Repatha, Otezla, Evenity |
| Allergan, INC. | $1,020.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.74 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $797.33 | 2019-2025 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $653.87 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $638.86 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $590.72 | 2019-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $552.74 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $521.31 | 2019-2024 |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Giannini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.